排序方式： 共有18条查询结果，搜索用时 18 毫秒
1.
运用高分辨率熔解曲线技术检测痛风患者SLC22A12基因intron5(+4668C/T)多态性 总被引：1，自引：0，他引：1
Objective To investigate a new single nucleotid polymorphism (SNP) intron5(+4668C/T) in SLC22A12 in primary gout patients and the association between clinical characteristics and genotypes. Methods One hundred and one primary gout patients and 186 healthy subjects were recruited into this study. Blood pressure, body mass index (BMI) was recorded. Serum uric acid, glucose, lipid and creatinine were detected. DNA was extracted from peripheral blood to amplify the fragment located in intron 5. The genotypes of SLC22A12 can be detected with high-resolution melting (HRM) assay, followed by sequencing analysis. Chi-square test was used for statistical analysis. Results ① A new SNP in intron 5 of SLC22A12 was identi-fied successfully by HRM, which was defined as intron 5 (+4668C/T). CC, CT and TT genotypes were unam-biguously distinguished with HRM technology, which was fully concordant with sequencing. ②The genotypes of CC, CT and TT in male and female groups were 28.1%, 33.7%, 38.2% and 20.0%, 47.1%, 32.9%, respectively.③ However, no significant differences of genotype distribution were found concerning BMI, blood pressure, creatinine, total cholesterol and triglyceride in both male group and female group. But the serum uric acid levels in the CC genotype were significantly higher than those with the CT+TT genotypes. ④ The genotype frequencies of CC and CT+TT in high uric acid group were remarkably different from those in low uric acid group (21.2%, 78.8%,; 35.0%, 65.0%; P<0.05). Conclusion A new SNP has been successfully discovered with HRM technology with simplicity, rapidity and accuracy. T allele of intron 5 (+4668C/T) may be a genetic protective factor for hyperuricemia among Chinese population. 相似文献
2.
3.
4.
5.
6.
7.
8.
目的 探讨CXCR4基因沉默对黑色素瘤侵袭及转移的影响及可能机制。方法 设计合成CXCR4特异性短发夹状RNA(shRNA)插入pSilencer载体,转染人高转移性黑色素瘤细胞株MV3、RT-PCR和Western blot法检测shRNA对靶基因CXCR4表达的影响。利用Transwell小室模型检测细胞体外侵袭能力,MTT法检测细胞体外增殖能力。通过裸鼠尾静脉瘤细胞注射,将转染后的细胞接种至裸鼠皮下,构建黑色素瘤转移模型,观察肿瘤生长情况。结果 CXCR4-shRNA能有效下调CXCR4基因的表达,降低黑色素瘤细胞增殖、体外侵袭及转移能力。RT-PCR及细胞免疫荧光显示,转染CXCR4-shRNA的黑色素瘤瘤MV3细胞系MMP-2表达下调;免疫组化结果显示,实验组裸鼠黑色素瘤瘤体及转移灶组织MMP-2的表达低于对照组。结论 shRNA介导的CXCR4基因沉默在体外实验能够显著抑制黑色素瘤细胞的生长和增殖活性,减弱体外侵袭能力,且体外产生抑瘤效应,明显降低肝、脑器官转移能力和定向肺转移能力。其机制可能与SDF-1/CXCR4信号途径阻断,进而抑制MMP-2的表达有关。 相似文献
9.
目的 SLC2A9是新近发现的尿酸转运子,该基因单核苷酸多态性可影响血清尿酸水平。本研究检测SLC2A9基因第6内含子rs7442295多态性在中国男性痛风和原发性高尿酸血症患者中的分布情况以及与尿酸代谢指标的相关性。方法 选取268例原发性痛风患者和288名健康志愿者,分别检测血压、体质量指数、血尿酸、血糖、血脂、肾功能水平,并同时提取外周血DNA,运用高分辨率熔解曲线(HRM)分析rs7442295基因型,并用测序法证实。统计学方法采用x2检验及t检验。结果 运用HRM技术能准确区分rs7442295 A/A和A/G基因型,而G/G基因型则在本研究人群中未发现。A/A和A/G基因型在人群分布频率分别是96.2％和3.8％。与健康对照组相比,痛风组的A/A和A/G基因型频率及A、G等位基因频率分布差异无统计学意义(x2=0.003,P=0.82; x2=0.003,P=1.00),但携带A/G基因型个体的尿酸水平[(293±100) μmol/L]明显低于携带A/A基因型的个体[(392±133) μmol/L]（t=2.426,P＜0.01）,且正常尿酸组内A/G基因型频率明显高于高尿酸组(x2=6.279,P=0.01）,基于HRM技术的基因分型结果与测序法所得结果完全一致。结论 SLC2A9基因rs7442295多态性可能是评估中国汉族男性人群原发性高尿酸血症危险性的一个遗传学标志,HRM技术简单、方便、快速,并实现闭管检测,非常适合单核苷酸多态性分析。 相似文献
10.
目的 探讨口服阿托伐他汀对高LDL-C血症相关的血小板异常活化功能的改善作用,阐明他汀类药物降低临床事件的新机制。方法 从2012年11月至2013年7月于华山医院门诊就诊人群中,纳入LDL-C≥4.14 mmol/L同时三酰甘油(triglycerides,TG) <1.7 mmol/L且未经调脂治疗和抗血小板治疗者作为研究对象,作为阿托伐他汀治疗组(AT组),从体检中心招募健康志愿者作为对照组。测定血小板最大聚集率(maximal platelet aggregation,MPAG),全血流式细胞检测法测定血小板活化标志物CD62p (P-选择素)和PAC-1 (GpⅡbⅢa)水平。对患者予以标准他汀治疗(阿托伐他汀20 mg/天),并于治疗后1个月、2个月随访检测以上指标。结果 AT组共纳入40例,其中33例完成研究;对照组纳入并完成35例。两组人群基线资料(年龄、性别、BMI、吸烟史、血压、冠心病家族史、血糖)无明显差异;AT组患者服用阿托伐他汀治疗后,TC、TG、LDL-C均明显下降(P<0.05);基线时AT组血小板最大聚集率与对照组相似(33.03%±15.87% vs.29.05%±17.75%,P=0.102),采用他汀治疗2个月后,AT组患者血小板最大聚集率较基线显著下降但差异无统计学意义(P=0.073)。治疗前AT组CD62p和PAC-1均高于对照组(1.72±0.96 vs.0.90±0.77,P<0.001;4.33±2.42 vs.2.63±2.03,P<0.01);阿托伐他汀治疗2个月后,CD62p和PAC-1分别为0.85±0.72和1.50±1.07,与治疗前比较,两者表达均明显下降(P<0.05)。结论 临床上阿托伐他汀可以改善高LDL-C相关的血小板活化。 相似文献